Logo image of ATOS

ATOSSA THERAPEUTICS INC (ATOS) Stock Fundamental Analysis

NASDAQ:ATOS - US04962H5063 - Common Stock

0.7775 USD
+0.03 (+4.5%)
Last: 8/22/2025, 8:00:00 PM
0.77 USD
-0.01 (-0.96%)
After Hours: 8/22/2025, 8:00:00 PM
Fundamental Rating

3

Taking everything into account, ATOS scores 3 out of 10 in our fundamental rating. ATOS was compared to 549 industry peers in the Biotechnology industry. ATOS has a great financial health rating, but its profitability evaluates not so good. ATOS is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ATOS had negative earnings in the past year.
ATOS had a negative operating cash flow in the past year.
ATOS had negative earnings in each of the past 5 years.
In the past 5 years ATOS always reported negative operating cash flow.
ATOS Yearly Net Income VS EBIT VS OCF VS FCFATOS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

With a Return On Assets value of -44.51%, ATOS perfoms like the industry average, outperforming 54.83% of the companies in the same industry.
The Return On Equity of ATOS (-49.78%) is better than 65.57% of its industry peers.
Industry RankSector Rank
ROA -44.51%
ROE -49.78%
ROIC N/A
ROA(3y)-28.82%
ROA(5y)-30.64%
ROE(3y)-30.53%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ATOS Yearly ROA, ROE, ROICATOS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

ATOS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATOS Yearly Profit, Operating, Gross MarginsATOS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for ATOS has been increased compared to 1 year ago.
Compared to 5 years ago, ATOS has more shares outstanding
There is no outstanding debt for ATOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ATOS Yearly Shares OutstandingATOS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ATOS Yearly Total Debt VS Total AssetsATOS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

2.2 Solvency

An Altman-Z score of 3.41 indicates that ATOS is not in any danger for bankruptcy at the moment.
The Altman-Z score of ATOS (3.41) is better than 73.95% of its industry peers.
There is no outstanding debt for ATOS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 3.41
ROIC/WACCN/A
WACCN/A
ATOS Yearly LT Debt VS Equity VS FCFATOS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

A Current Ratio of 9.17 indicates that ATOS has no problem at all paying its short term obligations.
ATOS has a better Current ratio (9.17) than 78.14% of its industry peers.
ATOS has a Quick Ratio of 9.17. This indicates that ATOS is financially healthy and has no problem in meeting its short term obligations.
ATOS has a Quick ratio of 9.17. This is in the better half of the industry: ATOS outperforms 78.14% of its industry peers.
Industry RankSector Rank
Current Ratio 9.17
Quick Ratio 9.17
ATOS Yearly Current Assets VS Current LiabilitesATOS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 4.17% over the past year.
EPS 1Y (TTM)4.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ATOS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 8.65% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-19%
EPS Next 2Y-17.66%
EPS Next 3Y-16.44%
EPS Next 5Y8.65%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATOS Yearly Revenue VS EstimatesATOS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2028 2029 2030 2031 2032 200M 400M 600M 800M
ATOS Yearly EPS VS EstimatesATOS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -20 -40 -60 -80

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ATOS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ATOS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATOS Price Earnings VS Forward Price EarningsATOS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATOS Per share dataATOS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

ATOS's earnings are expected to decrease with -16.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.66%
EPS Next 3Y-16.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ATOS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ATOSSA THERAPEUTICS INC

NASDAQ:ATOS (8/22/2025, 8:00:00 PM)

After market: 0.77 -0.01 (-0.96%)

0.7775

+0.03 (+4.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)11-10 2025-11-10
Inst Owners27.61%
Inst Owner Change-23.63%
Ins Owners0.04%
Ins Owner Change35.87%
Market Cap100.43M
Analysts82
Price Target5.74 (638.26%)
Short Float %2.95%
Short Ratio2.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.93%
Min EPS beat(2)-19.35%
Max EPS beat(2)13.5%
EPS beat(4)2
Avg EPS beat(4)3.24%
Min EPS beat(4)-19.35%
Max EPS beat(4)22.6%
EPS beat(8)5
Avg EPS beat(8)3.4%
EPS beat(12)8
Avg EPS beat(12)1.56%
EPS beat(16)12
Avg EPS beat(16)5.27%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-7.53%
EPS NQ rev (1m)-8.33%
EPS NQ rev (3m)7.14%
EPS NY rev (1m)-3.16%
EPS NY rev (3m)2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.74
P/tB 1.74
EV/EBITDA N/A
EPS(TTM)-0.23
EYN/A
EPS(NY)-0.29
Fwd EYN/A
FCF(TTM)-0.19
FCFYN/A
OCF(TTM)-0.19
OCFYN/A
SpS0
BVpS0.45
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -44.51%
ROE -49.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.82%
ROA(5y)-30.64%
ROE(3y)-30.53%
ROE(5y)-37.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 118.75%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.17
Quick Ratio 9.17
Altman-Z 3.41
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)157.54%
Cap/Depr(5y)108.53%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)4.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-40%
EPS Next Y-19%
EPS Next 2Y-17.66%
EPS Next 3Y-16.44%
EPS Next 5Y8.65%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y1.91%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.73%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.8%
OCF growth 3YN/A
OCF growth 5YN/A